Key facts
- Neomorph’s last known valuation is $324.0M (Mar 2026).
- It has raised $209.0M; the latest was Later Stage VC ($100.0M) in Mar 2026.
- Notable investors include Alexandria Venture Investments, Deerfield Management, Binney Street Capital, Longwood Fund, Regeneron Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Neomorph
- ·The full record, as it builds
Funding rounds
No funding rounds for Neomorph are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neomorph
Operator of a biotechnology company intended to focus on the science of targeted protein degradation. The company uses molecular glue technology to discover and develop medicines against undruggable targets, enabling medical practitioners to prosecute a pipeline of projects through clinical development.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 82
- Website
- neomorph.com/
- Ownership
- Privately Held (backing)
Neomorph doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neomorph shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neomorph in its N-PORT filings yet. We sweep new filings monthly.